Cargando…
P1028: PTG-300 (RUSFERTIDE) TREATMENT INTERRUPTION REVERSES HEMATOLOGICAL GAINS AND RESTORES THERAPEUTIC BENEFIT ON REINITIATION IN SUBJECTS WITH POLYCYTHEMIA VERA
Autores principales: | Kuykendall, A., Kremyanskaya, M., Ginsburg, Y., Pemmaraju, N., Ritchie, E., Gotlib, J., Valone, F., Khanna, S., Gupta, S., Hoffman, R., Verstovsek, S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430679/ http://dx.doi.org/10.1097/01.HS9.0000846980.34790.f7 |
Ejemplares similares
-
P1016: RUSFERTIDE (PTG-300) IMPROVES POLYCYTHEMIA VERA (PV) RELATED SYMPTOMS IN PV PATIENTS
por: Kuykendall, Andrew, et al.
Publicado: (2023) -
P1048: PHARMACOKINETIC AND PHARMACODYNAMIC EFFECTS OF RUSFERTIDE IN POLYCYTHEMIA VERA: RESULTS FROM AN ONGOING PHASE 2 STUDY IN PATIENTS WITH ELEVATED HEMATOCRIT VALUES
por: Kremyanskaya, Marina, et al.
Publicado: (2023) -
Real-world treatments and thrombotic events in polycythemia vera patients in the USA
por: Verstovsek, Srdan, et al.
Publicado: (2023) -
Updates in the management of polycythemia vera and essential thrombocythemia
por: Bose, Prithviraj, et al.
Publicado: (2019) -
Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib
por: Bryan, Jeffrey C., et al.
Publicado: (2016)